• 4 Patients typically receive between 3 and 6 cycles of carboplatin and paclitaxel (or another platinum-based regimen), followed by completion surgery and postoperative chemotherapy. (ahdbonline.com)
  • Alymsys, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). (mdtodate.com)
  • The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel. (mdtodate.com)
  • Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease. (mvasi.com)
  • Ovarian Cancer (OC) MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery. (mvasi.com)
  • MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (mvasi.com)
  • You start taking Avastin® (bevacizumab) with carboplatin and paclitaxel (chemotherapy) to treat your advanced (stage III or IV) ovarian cancer. (runyoncanyon-losangeles.com)
  • Alymsys, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. (mdtodate.com)
  • and (7) epithelial ovarian, fallopian tube or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for platinum-resistant recurrent disease in people receiving no more than two prior chemotherapy regimens. (mmitnetwork.com)
  • MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments. (mvasi.com)
  • In an open, randomized comparative study, patients treated with Hycamtin demonstrated a statistically significantly longer progression-free survival (time to progression) and a numerically superior response rate than patients treated with paclitaxel (Taxol). (bio.net)
  • SmithKline Beecham's Hycamtin for Recurrent Ovarian Cancer Recommended for Approval by FDA Committee BETHESDA, Md., April 19, 1996 -- The Oncologic Drugs Advisory Committee of the Food and Drug Administration today unanimously recommended approval of Hycamtin (topotecan hydrochloride) from SmithKline Beecham for the treatment of patients with metastatic ovarian cancer after failure of initial or subsequent chemotherapy. (bio.net)
  • Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. (uci.edu)
  • BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. (uci.edu)
  • Ovarian cancer subtypes can now be identified with different clinical and genomic characteristics, which may influence response to treatments beyond the standard carboplatin/paclitaxel regimen. (jnccn.org)
  • Topotecan inhibits topoisomerase I, inhibiting DNA replication. (medscape.com)
  • Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (avastin.com)
  • Notably, his work involving gemcitabine and nab-paclitaxel combination therapy in pancreatic cancer patients was one of the first to demonstrate improved response rates, progression-free survival, and overall survival in patients with metastatic pancreatic cancer. (nfcr.org)
  • The study randomly assigned patients 2:1 to olaparib (n = 178) or treatment of physician's choice, which included paclitaxel, topotecan, gemcitabine, or pegylated liposomal doxorubicin. (clearityfoundation.org)
  • 5. Salvage weekly paclitaxel in recurrent ovarian cancer. (nih.gov)
  • 7. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. (nih.gov)
  • 20. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. (nih.gov)
  • We evaluated the sequential use of carboplatin, paclitaxel and topotecan in patients with advanced, previously untreated ovarian cancer. (bvsalud.org)
  • In total, 43 patients with advanced ovarian cancer and >1 cm residual disease were treated with sequential carboplatin (area-under-the-curve (AUC) 5 days 1 and 22), paclitaxel (175 mg m(-2) days 43 and 64) and topotecan (1.5 mg m(-2) daily for 5 days from days 85, 106, 127 and 148). (bvsalud.org)
  • This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors , ovarian cancer that has come back or does not respond to treatment, or primary peritoneal cancer . (ucbraid.org)
  • To assess the confirmed response rate for patients with epithelial ovarian cancer , fallopian tube cancer or primary peritoneal carcinoma treated with the combination of ABT-888 and weekly topotecan. (ucbraid.org)
  • Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. (nih.gov)
  • The recommended dose is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and paclitaxel for 6 to 8 cycles, followed by Bevacizumab (Avastin®) 15 mg/kg every 3 weeks as a single agent until disease progression. (ptmasterguide.com)
  • Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. (avastin.com)
  • 19. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. (nih.gov)
  • These highlights do not include all the information needed to use TOPOTECAN HYDROCHLORIDE FOR INJECTION safely and effectively. (nih.gov)
  • Topotecan Hydrochloride for Injection can cause severe myelosuppression. (nih.gov)
  • To determine the maximum tolerated dose of the combination of veliparib (ABT-888) and weekly topotecan (topotecan hydrochloride) in adult patients with advanced solid tumors . (ucbraid.org)
  • OUTLINE: This is a phase I, dose-escalation study of veliparib and topotecan hydrochloride followed by a phase II study. (ucbraid.org)
  • Patients receive veliparib orally (PO) on days 1-3, 8-10, and 15-17 (veliparib is omitted on days 1-3 of course 2) and topotecan hydrochloride intravenously (IV) over 30 minutes on days 2, 9, and 16. (ucbraid.org)
  • The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel. (ptmasterguide.com)
  • In the present study, the MTT assay was employed to evaluate the therapeutic efficacy of IPAT or IPAT in combination with paclitaxel (PTX) in endometrial cancer cell lines and primary cultures of endometrial cancer. (bvsalud.org)
  • Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. (uchicago.edu)
  • Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. (uchicago.edu)
  • CP+Avastin→Avastin=carboplatin (AUC 6) and paclitaxel (175 mg/m 2 ) for 6 cycles, with concurrent Avastin started at cycle 2, followed by single-agent Avastin q3w for a total of up to 22 cycles of therapy. (avastin.com)
  • Subsequently, she received six cycles of paclitaxel (175 mg/m 2 ) and carboplatin (AUC 5) until March 2014. (bmj.com)
  • To determine whether topotecan stimulates adenosine diphosphate (ADP)-ribose polymer formation in circulating peripheral blood mononuclear cells. (ucbraid.org)
  • Topotecan 1.5 mg/m2 daily was administered as a 30-minute infusion for 5 consecutive days on a 21-day cycle. (nih.gov)